Isolation of New Transmissible Herpesvirus Suggests Additional Therapeutic Approaches for KS

Publication
Article
OncologyONCOLOGY Vol 10 No 3
Volume 10
Issue 3

A study demonstrating the existence of a new transmissible herpesvirus may lead to additional therapeutic approaches for Kaposi's sarcoma (KS), a cancer that remains one of the major AIDS-associated malignancies. The study findings were reported at The American Society of Hematology's 37th Annual Meeting in Seattle.

A study demonstrating the existence of a new transmissible herpesvirusmay lead to additional therapeutic approaches for Kaposi's sarcoma(KS), a cancer that remains one of the major AIDS-associated malignancies.The study findings were reported at The American Society of Hematology's37th Annual Meeting in Seattle.

Kaposi's sarcoma can be fatal, and is characterized by the growthof lesions on the skin, in the gastrointestinal tract, or in thelungs, brains, or other organs. The cause of KS remains unclear,although present evidence suggests the involvement of a sexuallytransmitted agent.

The study, conducted by researchers at Cornell University MedicalCollege, isolated a fragment of herpes viral DNA (KSHV-DNA) fromAIDS-associated KS lesions and from AIDS-related body cavity-basedlymphomas. This DNA fragment also was found in non-AIDS relatedKS, further reinforcing the idea of an association between thenew herpesvirus and the pathology of KS.

When a tumor cell line that carries KSHV-DNA was utilized to isolateviral particles produced by these cells, it was noted that theKSHV-DNA was contained inside the viral particles since it wasprotected from the action of a DNA-degrading enzyme. The viruscontained in the isolate was infectious and could transmit theKSHV-DNA to human B-lymphyocytes.

This infection was blocked by foscarnet (Foscavir), an inhibitorof viral DNA replication that is currently approved by the FDAfor the treatment of cytomegalovirus retinitis, an opportunisticviral infection. Further studies may establish the potential offoscarnet as a treatment for KS.

Recent Videos
Accelerated approval of afami-cel may expand access to therapy for patients who are unable to live near certain treatment centers.
Treatment with afami-cel may offer improved quality of life to patients with metastatic synovial sarcoma compared with continuous chemotherapy.
The difference in adverse effect profiles between sorafenib and nirogacestat may make one treatment more appealing than the other for certain patients with desmoid tumors, says Brian Van Tine, MD, PhD.
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Related Content